Mental Health Provider Expands Psychedelic-Assisted Therapy For Chronic & Serious Medical Illnesses

Numinus Wellness Inc. NUMIF announced the launch of its new clinical program, ketamine for chronic and serious medical illness, to be first introduced at Utah, BC and Quebec clinics and then expanded to Numinus' remaining facilities.

The company’s model includes psychedelic production, research and clinical care, with the goal of healing rather than managing symptoms of depression, anxiety, trauma, pain and substance use.

According to Numinus CSO Dr. Paul Thielking, numerous patients develop adjustment disorders, including depression and anxiety, when going through the various stages of chronic and serious medical illness for which ketamine-assisted therapy has been validated as effective in addressing these symptoms.

Dr. Thielking expects this kind of therapy will provide the opportunity to alleviate patient suffering, while at the same time expanding Numinus' model of accessible care to more populations.

The new program will address chronic and serious medical illnesses, which encompass various diagnoses ranging from terminal cancer to chronic pain, as explained Numinus’ VP of product and protocol development Dr. Neil Barclay. 

“In the US alone, six million people could benefit from palliative care, but current treatments have gaps that leave patients struggling to cope with distress. Numinus’ program addresses this gap by providing safe, evidence-based ketamine-assisted therapy that is specifically designed for this patient population and serves as an adjunct to patients’ existing treatment.” 

That said, the program will offer KAP along with additional community support towards improving patients’ physical, emotional, mental as well as spiritual suffering. Treatment will be provided by healthcare professionals specifically trained in chronic and serious medical illness, who will work with each patient’s existing healthcare team so as to effectively provide them with an integrated experience.

Other Business Announcements

Numinus will present the Salt Lake City premiere of Dosed 2: Trip of a Lifetime, a documentary following a terminally-ill patient’s journey through psychedelic-assisted therapy, to raise further awareness of the positive impact of psychedelic-assisted therapy for palliative and serious illness patients. The date is November 8, 2022. 

Additionally, integration of recently-acquired Novamind clinic services, including the latest consolidation of the nearby Murray and Salt Lake City clinics to streamline clinic operations and hopefully provide an expanded service offering to clients in the region while also reducing operating costs.

Photo courtesy of RODNAE Productions on Pexels and Doc James on Wikimedia Commons.